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This case study demonstrates the potential exacer-
bation of inﬂammatory bowel disease secondary
to using isotretinoin (Roaccutane
®) for treatment
of severe acne.
Case report
A 27-year-old female medical student experienced
an episode of intermittent bloody diarrhoea for
6 weeks. She had no prior illnesses, no family
history of note and had not undergone any
recent travel. Routine blood and stool tests by
her GP were normal. A colonoscopy showed
patchy moderately active colitis and biopsies
revealed patchy mild to moderate chronic active
inﬂammation with cryptitis and no granulomas.
The features were in keeping with, but not diag-
nostic of, ulcerative colitis. Since symptoms had
completely abated, the patient decided against
starting treatment.
Six months later, she started a 16-week course
of isotretinoin 40 mg daily for acne vulgaris.
During week 14 of the treatment she developed
bloody diarrhoea three to four times a day,
which was treated with enteric coated mesalasine
by her GP.
At the end of the isotretinoin course her symp-
toms worsened – her stool frequency increased to
15 bloody motions daily with a CRP of 46 mg/L.
She was treated with intravenous hydrocortisone
and high-dose mesalazine. However, after 3 days
the stool frequencyand CRP had not fallen. A ﬂex-
ible sigmoidoscopy revealed severely active colitis
with multiple superﬁcial ulcers. Intravenous
ciclosporin produced no response and a subtotal
colectomy and ileostomy was performed. His-
tology showed severe acute-on-chronic ulcerative
colitis with no viral inclusions or granulomas.
Discussion
Inﬂammatoryboweldisease(incorporatingCrohn’s
disease and ulcerative colitis) is a common con-
dition affecting 1 in 400 people in the UK, and the
incidence is continuing to rise.
1 It is usually diag-
nosed in young adults, mostly between the ages of
20 and 40 years, but can present at any age.
Acnevulgarisisacommonskinconditionaffect-
ingupto80%ofadolescents,with13%visitingaGP
and 0.3% seeing a dermatologist.
2 Initial therapy
includestopicaltreatmentssuchasbenzylperoxide
and clindymicin and systemic antibiotics such as
tetracyclines for resistant cases. Those not respond-
ing to systemic and topical therapy can be offered a
4–6 month course of isotretinoin – a vitamin A
derivative. Its use is controversial due to rare side-
effects of depression and suicide
3,4 and it should
be avoided in young women due to its teratogeni-
city. A transient elevation in liver transaminases is
relatively common and all patients should have
their liver enzymes monitored. Other gastro-
intestinal side-effects were thought to be rare,
however, this case report highlights the under-
appreciated, potentially serious side-effect of intes-
tinal inﬂammation.
The product literature on isotretinoin includes
gastrointestinal side-effects with an incidence of
less than 1:10,000 and includes colitis, ileitis and
inﬂammatory bowel disease.
3 The Medicines and
Healthcare products Regulatory Agency have
received a total of 325 gastrointestinal adverse
effects associated with isotretinoin between 1966
and 2009. Twenty-four of these cases were exacer-
bations of ulcerative colitis, three exacerbations of
crohn’s disease and 19 were described as ‘inﬂam-
matory bowel disease and non-infective colitis’.
5
The statistical nature of the data means that the
history of the cases is not known.
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CASE REPORT
1There have been several case reports dating
back over two decades of isotretinoin inducing
or exacerbating inﬂammatory bowel disease.
Martin et al. reported a 17-year-old boy, with no
prior history of bowel disease, had developed
acute proctosigmoiditis after receiving isotretinoin
for four weeks. His symptoms resolved after with-
drawing the drug.
6
Another 17-year-old boy was diagnosed with
ulcerative colitis post isotretinoin treatment. Five
months after symptoms ﬁrst presented, the patient
required a subtotal colectomy and ileostomy.
7
Spada et al. described a case of a 22-year-old man
diagnosed with pan-enteritis after taking isotreti-
noin for 15 days.
8 The Netherlands Pharmacovigi-
lance Centre reports three cases of inﬂammatory
bowel disease being associated with isotretinoin
between1985and2005,noneofwhichhadpriorhis-
tories of intestinal disease. They all developed
inﬂammatoryboweldiseaseaftercompletingisotre-
tinointreatment,andrequiredaminosalicylatesand
steroids to control their symptoms.
9
Reddy et al. reviewed 85 cases (36 ulcerative
colitis, 30 Crohn’s disease and 19 unclassiﬁed
colitis) associated with isotretinoin reported to
the US Food and Drug Administration (FDA)
between 1997 and 2002.
10 Each case was given a
Naranjo probability score of the likelihood of iso-
tretinoin causing an adverse effect. Of the 85
cases, four were thought to be a ‘highly probable’,
58 reported as ‘probable’ and 23 as ‘possible’.
None of the reports were considered ‘doubtful’.
The mechanism by which (endogenous and
exogenous) retinoids cause orexacerbate intestinal
inﬂammation is not understood. Retinoic acid
affects intestinal epithelial growth and is involved
in cell repair and apoptosis. Retinoids also impair
neutrophil chemotaxis, a mechanism involved in
Crohn’sdisease.
11 Theproductionofinducedregu-
latory Tcells (iTreg) and T helper 17 (Th17) cells is
also controlled by retinoic acid – these also being
involved in gut epithelial homeostasis.
12
The potential for isotretinoin to cause orexacer-
bate existing colitis is overlooked. Any patient
with pre-existing inﬂammatory bowel disease
should not be prescribed isotretinoin. Patients
should be informed of the risk of developing
inﬂammatory bowel disease and advised to stop
the medication if abdominal symptoms occur.
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